ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders

Author(s): Cheong-Meng Chong , Nana Ai , Simon Ming-Yuen Lee .

Journal Name: Current Drug Targets

Volume 18 , Issue 4 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Rho-associated protein kinase (ROCK) is a serine-threonine kinase originally identified as a crucial regulator of actin cytoskeleton. Recent studies have defined new functions of ROCK as a critical component of diverse signaling pathways in neurons. In addition, inhibition of ROCK causes several biological events such as increase of neurite outgrowth, axonal regeneration, and activation of prosurvival Akt. Thus, it has attracted scientist’s strong attentions and considered ROCK as a promising therapeutic target for the treatment of neurodegenerative disorders including Alzheimer disease, Parkinson’s disease, Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis. However, ROCK has two highly homologous isoforms, ROCK1 and ROCK2. Accumulated evidences indicate that ROCK1 and ROCK2 might involve in distinct cellular functions in central nervous system (CNS) and neurodegenerative processes. This review summarizes recent updates regarding ROCK isoformspecific functions in CNS and the progress of ROCK inhibitors in preclinical studies for neurodegenerative diseases.

Keywords: Axonal regeneration, central nervous system, fasudil, isoforms, LIMK, neurodegenerative diseases, rock.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 4
Year: 2017
Page: [455 - 462]
Pages: 8
DOI: 10.2174/1389450117666160401123825
Price: $58

Article Metrics

PDF: 68
HTML: 4